UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) October 12, 2006
CepTor Corporation
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| |
|
|
| 001-32496
|
|
11-2897392 |
| |
| (Commission File Number)
|
|
(IRS Employer Identification No.) |
| |
|
|
200 International Circle, Suite 5100
Hunt Valley, Maryland
|
|
21030-1350 |
| |
| (Address of Principal Executive Offices)
|
|
(Zip Code) |
(410) 527-9998
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On October 12, 2006, CepTor Corporation (the “Company”) issued a press release disclosing that
the results of testing Neurodur in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model
(the standard animal model used in multiple sclerosis (MS) testing) were published in the Journal
of Neuroimmunology and that the data indicated that the reduction of clinical symptoms of MS in EAE
mice treated with oral Neurodur were statistically significant.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| |
|
|
| Exhibit No. |
|
Description |
99.1
|
|
Press Release |